Illumina Infinium BeadChips Selected by Germany's National Genome Research Network to Support One of the World's Largest Genetic Disease Studies to Date

Illumina, Inc. (NASDAQ:ILMN) today announced that Germany’s National Genome Research Network (NGFN) has selected Illumina’s Infinium® HumanCNV370-Duo, HumanHap300-Duo, and HumanHap550 BeadChips to conduct one of the world’s largest genetic research projects to date. Scientists will genotype 8,000 patients and controls using Illumina’s tools to investigate genetic variations to better understand underlying causes of 25 complex diseases. Diseases to be studied using Illumina’s tools include several mental health diseases such as Bipolar disease and Schizophrenia, in addition to Parkinson’s disease, Alzheimer’s disease, Alcohol addiction, Inflammatory Bowel Disease, and Psoriasis. "Genome-wide association studies will provide the life science community with genetic maps for some of the most complex diseases,” said Professor Stefan Schreiber of the University of Kiel. "The National Genome Research Network aims to drive this analysis to a meta-level above single (indication) phenotypes and thus understand genetic risk as an overarching susceptibility for general processes like inflammation, degeneration, or cancer.” Researchers at the NGFN will compare patients’ data with the data of healthy individuals to identify genetic variations and differences associated with the diseases, ultimately aiding in the development of better treatment options. Additionally, scientists are interested in revealing the genetic causes of longevity in order to understand the principles of the aging process and identify new treatment approaches for age-related diseases. "In accelerated timeframes, the HumanHap300-Duo and HumanHap550, two of the three Infinium BeadChips to be used in the NGFN study, have been used to identify novel variants linked to complex conditions such as Type-2 diabetes, Crohn’s disease, Parkinson’s disease, and Lou Gehrig’s disease,” said Jay Flatley, Illumina’s Chief Executive Officer. "With these types of results, we are not only excited that scientists at the National Genome Research Network have selected Illumina’s technology to help perform one of the world’s largest genetic research projects to date, but that they have the same accelerated discoveries as other researchers.” In addition to Illumina’s HumanHap300-Duo and HumanHap550 BeadChips, which can detect up to 317,000 and 550,000 genetic variations on a single BeadChip, respectively, the new HumanCNV370-Duo BeadChip will be used as part of the NGFN study. This BeadChip contains 15,000 non-polymorphic probes and is specifically designed to interrogate novel copy number variation regions. Unique to the HumanHap300-Duo and HumanCNV370-Duo, researchers will utilize the BeadChips’ dual-sample formats to simultaneously type a disease sample and a normal sample, allowing direct comparison of data, eliminating array-to-array variability. About the National Genome Research Network The National Genome Research Network (NGFN) is a large scale biomedical program initiated by the German Federal Ministry for Education and Research (BMBF). The research activity of the NGFN focuses on investigating genetic causes of common diseases. To accomplish this, a unique organizational structure has been created so that leading experts from both systematic genome research and clinical research can collaborate closely. Together, they seek to understand the complex control mechanisms of the human body at the DNA, RNA and protein level in order to find keys to new treatments for currently incurable diseases. For more information about the NGFN, please visit the NGFN website at www.ngfn.de. About Illumina Illumina (www.illumina.com) is developing next-generation tools for the analysis of genetic variation and function. "Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: this release may contain forward-looking statements that involve risks and uncertainties. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are the costs and outcome of Illumina’s litigation with Affymetrix and our ability (i) to integrate effectively our recent acquisition of Solexa, Inc., (ii) to develop and commercialize further our BeadArray™, VeraCode™, and Solexa® technologies and to deploy new gene expression and genotyping products and applications for our technology platforms, (iii) to manufacture robust micro arrays and Oligator® oligonucleotides, (iv) to integrate and scale our VeraCode technology, (v) to scale further oligo synthesis output and technology to satisfy market demand derived from our collaboration with Invitrogen, together with other factors detailed in our filings with the Securities and Exchange Commission including our recent filings on Forms 10-K and 10-Q or in information disclosed in public conference calls, the date and time of which are released beforehand. We disclaim any intent or obligation to update these forward-looking statements beyond the date of this release.